<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02178657</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2013-002135-15</org_study_id>
    <nct_id>NCT02178657</nct_id>
    <nct_alias>NCT02290483</nct_alias>
  </id_info>
  <brief_title>Intra-arterial Bone-marrow Mononuclear Cells Infusion for Acute Ischemic Stroke</brief_title>
  <official_title>Intra-arterial Autologous Bone-marrow Mononuclear Cells Infusion for Acute Ischemic Stroke. A Phase II, Open-label, Multicenter, Randomized and Controlled Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andalusian Initiative for Advanced Therapies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Andalusian Initiative for Advanced Therapies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial aims to test that intra-arterial injection of autologous bone marrow mononuclear
      cells in acute ischemic stroke patients is safe and improves neurological outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study in which the patients will be included diagnosed of ischemic stroke sharply
      in the territory of the cerebral average artery that there fulfill criteria of incorporation
      and none of those of exclusion and that they have signed the informed assent. 76 patients
      will randomize in proportion 2:1:1 in a group control that will receive only medical
      conventional treatment and in two groups of intervention that will receive an unique
      intra-arterial infusion of mononuclear autologous bone marrow stem cells (one group of dose
      of 2 millions of BMSC for kilogram of weight and another group of dose of 5 millions of BMSC
      for kilogram of weight). The three groups of patients will be followed for 24 months. The
      randomization will be stratified depending on the NHSS score. This clinical trial has a
      voluntary substudy to obtain information on plasma biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disability</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of patients with modified Rankin Scale scores of 0-2 at 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Functional outcomes</measure>
    <time_frame>6 months</time_frame>
    <description>Functional outcome measure by National Institute of Health Stroke Scale and Barthel at 6 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Infarct volume</measure>
    <time_frame>6 months</time_frame>
    <description>Infarct volume change between baseline (DWI) and 6 months (FLAIR)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants with new-onset seizures as a Measure of Safety and Tolerability</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Functional outcomes</measure>
    <time_frame>6 months</time_frame>
    <description>Categorical shift in mRS ordinal (0-6) scale</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Bone marrow transplantation low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-arterial autologous bone marrow mononuclear cells injection (dose 2x10^6 per kilogram)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bone marrow transplantation high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-arterial autologous bone marrow mononuclear cells injection (dose 5x10^6 per kilogram)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Autologous bone marrow mononuclear cell intra-arterial injection</intervention_name>
    <arm_group_label>Bone marrow transplantation low dose</arm_group_label>
    <arm_group_label>Bone marrow transplantation high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with middle cerebral artery (MCA) acute ischemic stroke.

          -  Time of stroke onset is known and treatment can be started between day 1 and 7 of
             onset.

          -  DWI-MRI has reliably shown acute MCA ischemic lesions

          -  Magnetic resonance angiography (MRA) must confirm ipsilateral MCA permeability

          -  National Institute of Health Stroke Scale score of 6-20 at inclusion

          -  Age 18-80 years

          -  Written informed consent has been obtained

        Exclusion Criteria:

          -  Hemorrhagic stroke or symptomatic hemorrhagic transformation

          -  Lacunar infarction

          -  Preocclusive stenosis or total occlusion of ipsilateral carotid artery

          -  Worsening of ≥4 points in National Institute of Health Stroke Scale in the 24 hours
             previous to inclusion, attributable to edema or hemorrhagic transformation or
             suspicious of malignant edema

          -  Decrease of consciousness with a Glasgow Coma Scale of &lt;8 points

          -  Patients with present or previous malignant disease during the last 5 years, except
             for basal cell carcinoma

          -  Contraindication for MRI or for bone marrow harvest

          -  Previous diagnosis of neurodegenerative disease

          -  Acute heart failure

          -  Hepatic or renal dysfunction (creatinine &gt;2mg/dL)

          -  Coagulopathy

          -  Severe co-morbidity

          -  Pregnancy, childbearing potential (unless it is certain that pregnancy is not
             possible) or breast feeding

          -  Modified Rankin Score (mRS) before stroke of ≥2

          -  Participation in any clinical trial in the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Moniche, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospitales Universitarios Virgen del Rocio</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natividad Cuende, MD, MPH, PhD</last_name>
    <phone>(+34) 955048366</phone>
    <email>natividad.cuende.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Valverde Moyano, MD</last_name>
      <email>rvalverdemoyano@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospitales Universitarios Virgen del Rocio</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Moniche, MD, PhD</last_name>
      <phone>+34 955012593</phone>
      <email>pmoniche@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospitales Universitarios Virgen Macarena</name>
      <address>
        <city>Seville</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Ángel Gamero, MD</last_name>
      <phone>(+34) 955008681</phone>
      <email>mangel.gamero.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2014</study_first_submitted>
  <study_first_submitted_qc>June 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2014</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospitales Universitarios Virgen del Rocío</investigator_affiliation>
    <investigator_full_name>Francisco Moniche</investigator_full_name>
    <investigator_title>Neurologist</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Cell therapy</keyword>
  <keyword>Bone marrow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

